Skip to main content
. 2019 May 16;7:298. doi: 10.3389/fchem.2019.00298

Figure 6.

Figure 6

SLC35F2 is required for cell entry of YM155 analogs and stemotoxic activity (A) Scheme for knock out (KO) of SLC35F2 targeting Exon 7. (B) Percentage of mutations quantified from Sanger sequencing and relative contribution of each sequence of wild type (WT) and SLC35F2 KO hESCs was graphically presented. (C) Light microscope images of hESCs (WT) and SCL35F2 knock out hESCs (KO) after treatment of 20 nM of YM155 and YM155 analogs (Scale bar = 300 μm). (D) FACS analysis for Annexin-V/7-AAD staining after indicative concentration of YM155 in WT or KO (left), Percentages of live cells (Annexin-V negative and 7-AAD negative Cells) were presented as a bar graph (right) (n = 3).